IKIchiro Kinoshita

Ichiro Kinoshita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ichiro Kinoshita has a total of 174 co-authors. Here are the top co-authors by number of shared publications:

  • Masaharu Nishimura

    Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Hokkaido Medical Research Institute for Respiratory Diseases, Sapporo, Japan

    11 shared publications
  • Hirotoshi Dosaka-Akita

    Affiliation Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    10 shared publications
  • Junko Kikuchi

    Division of Clinical Cancer Genomics Hokkaido University Hospital Hokkaido Japan

    9 shared publications
  • Yasushi Shimizu

    Department of Medical Oncology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan

    7 shared publications
  • Eiki Kikuchi

    Department of Respiratory Medicine, Faculty of Medicine Hokkaido University Sapporo Japan

    5 shared publications
  • Akihiro Sakurai

    Division of Clinical Genomics, Department of Genomic and Preventive Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, sapmed.ac.jp

    4 shared publications

Latest Publications

  • Open Access

    Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK -Altered Advanced Solid Tumors: A Phase II TACKLE Trial (NCCH1712/MK003)

    by Hitomi S. Okuma, Ayumu Arakawa, Akihiro Hirakawa, Shinji Kohsaka, Tomozo Yamada, Kenta Anjo, Kazumi Kurishita, Kenichi Nakamura, Takashi Kohno, Shigemi Matsumoto, et al.

    Purpose: Anaplastic lymphoma kinase (ALK) alterations occur in a range of rare malignancies; however, prospective evidence supporting alectinib beyond lung cancer remains limited. We evaluated the activity and safety of alectinib in patients with advanced ALK-altered solid tumors. Patients and Methods: In this open-label, multicenter phase II study, patients with advanced ALK-altered solid tumors received alectinib (capsule or suspension). The primary endpoint was centrally confirmed objective response rate (ORR) per RECIST v1.1, evaluated using a Bayesian design (expected ORR, 40%; threshold, 10%) in patients receiving intact capsules (cohort A). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: Twenty-six patients (age, 8 months–78 years) with 11 tumor types were enrolled; inflammatory myofibroblastic tumor (IMT; n = 9) and neuroblastoma (n = 5) were the most common. ALK alterations included fusions/rearrangements (n = 19), mutations (n = 5), and amplifications (n = 2). The median follow-up was 15 months. In cohort A (n = 16 with measurable disease), the centrally reviewed ORR was 43.8%, meeting the primary endpoint. Among evaluable patients (n = 24), the ORR was 54.2%, and the DCR was 75%. The median PFS and OS were 24.9 and 38.8 months, respectively. Patients with ALK fusions/rearrangements (n = 17) had ORR and DCR of 76.5% and 88.2%, respectively. All patients with IMT achieved tumor shrinkage (ORR, 87.5%). Patients ≤15 years (n = 11) had ORR and DCR of 63.6% and 100%, respectively. Grade ≥3 treatment-related adverse events occurred in 15.4% (n = 4), with no treatment-related deaths. Conclusions: Alectinib demonstrated meaningful, durable responses with acceptable safety across ALK-altered solid tumors, particularly in patients with ALK fusions, supporting further tumor-agnostic development.

  • Open Access

    Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial ( NCCH1901 ) Subcohort

    by Masashi Kanai, Kuniko Sunami, Tatsunori Shimoi, Satoshi Nishiwaki, Ichiro Kinoshita, Tetsuhiro Yoshinami, Chigusa Morizane, Yusuke Sato, Toshio Kubo, Mamoru Ito, et al.

    Comprehensive genomic profiling (CGP) tests can identify putative biomarkers for immune checkpoint inhibitors (ICIs), including tumor mutational burden (TMB); however, their clinical utility remains uncertain. In this study, the efficacy and safety of nivolumab treatment based on the CGP results were investigated using a subcohort from the BELIEVE trial (NCCH1901; jRCTs031190104). This trial aims to improve drug accessibility for patients with advanced solid tumors harboring actionable genetic variants through off‐label drug administration. Patients for whom off‐label nivolumab treatment was proposed based on CGP results were eligible. Nivolumab was administered until disease progression or unacceptable toxicity. The primary endpoint was the best objective response rate (ORR) in patients with measurable disease. Secondary endpoints included progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Among 60 enrolled patients, 56 patients who received study treatment were included in the analysis. TMB‐High was the most frequent biomarker prompting nivolumab treatment (47/56, 83.9%), followed by CD274 (PD‐L1) amplification (6/56, 10.7%) and CDK12 inactivating variants (3/56, 5.4%). Among 50 patients with measurable disease, the ORR was 16.0% (95% confidence interval [CI], 7.2–29.1) and the DCR was 40.0% (95% CI, 26.4–54.8). Median PFS and OS were 2.7 months (95% CI, 2.2–4.3) and 7.2 months (95% CI, 4.4–9.0), respectively. Although a subset of patients achieved durable responses, nivolumab treatment guided by CGP results demonstrated limited efficacy. The predictive value of TMB‐High may differ across tumor types, and integration with other clinicogenomic factors is warranted to improve its predictive accuracy.

  • Open Access

    Earlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype‐Matched Therapy: A Prospective Single‐Institution Study

    by Kazusa Nofuji, Tasuku Mariya, Tomohiro Kubo, Ayako Murota, Mizue Teramoto, Shutaro Habata, Motoki Matsuura, Masahiro Iwasaki, Aki Ishikawa, Kohichi Takada, et al.

    Background and Aims: Personalized medicine utilizing comprehensive cancer genomic profiling (CGP) for gynecologic cancers is still in its early stages and faces numerous challenges. In this study, we aimed to elucidate the current status of CGP for gynecologic cancers at our institution. Methods: We prospectively analyzed 44 cases of gynecologic cancers that underwent CGP (FoundationOne CDx or Liquid CDx) from March 2020 to July 2022, evaluating the CGP results and clinical outcomes. Results: Forty‐one cases underwent FoundationOne CDx and four underwent FoundationOne Liquid CDx testing. The distribution of cancer types consisted of 10 cases of cervical cancer, 21 cases of ovarian cancer, 7 cases of endometrial cancer, and 6 cases of sarcomas. Actionable genomic alterations were identified in 42 cases (95.5%), with 16 cases (36.4%) presenting clinically for genotype‐matched therapy (GMT). However, GMT was administered in only three cases (6.8%). Among the cases without GMT, four experienced a deterioration in overall physical condition and two had complications as the reason for nonimplementation. Consideration of presumed germline pathogenic variants occurred in 10 cases (22.2%), with confirmatory testing conducted in two. In survival analysis using the Cox proportional hazards model, the presence of PIK3CA mutations was identified as being potentially associated with adverse prognosis (hazard ratio: 2.73, 95% confidence interval: 1.15–6.49, and p = 0.023). Conclusion: To enhance the prognosis of gynecologic cases, earlier CGP testing to expand the opportunities for GMT and the proactive introduction of PIK3CA ‐related clinical trials might be crucial.

  • Open Access

    Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan

    by Takuro Noguchi, Shin Ariga, Rika Moku, Junko Kikuchi, Toraji Amano, Takuya Maeda, Kosuke Ishikawa, Akihiko Shiiya, Tomohiro Goda, Yoshihito Ohhara, et al.

    PURPOSE: Precision medicine plays an important role in the treatment of patients with advanced melanoma. Despite its high incidence in White patients, advanced melanoma is rare in Asian countries, hampering prospective clinical trials targeting the Asian population. This retrospective study aimed to elucidate the real-world molecular diagnoses and outcomes of Japanese patients with melanoma using comprehensive genome profiling (CGP). MATERIALS AND METHODS: Patients with melanoma who completed standard anticancer medical treatments (including those expected to complete the treatments) underwent CGP, which is covered by the National Health Insurance. We analyzed the results and clinical annotations of 569 patients registered before August 2023 in a national database. RESULTS: Skin, mucosal, and uveal melanomas accounted for 64%, 28%, and 7% of cases, respectively. Patients with BRAF , NRAS , NF1 , and KIT variants represented 25%, 20%, 17%, and 17%, respectively. Eighty-two percent of BRAF , 97% of NRAS , 69% of NF1 , and 54% of KIT were actionable alterations (ie, BRAF classes I, II, and III, NRAS Q61, G12, G13, NF1 loss-of-function, KIT gain-of-function variants). BRAF V600E/K variants occurred in 22% of skin and 2% of mucosal melanomas, but not in uveal melanomas. The mean tumor mutation burden in cutaneous melanomas was 4.2 variants/Mb. Patients previously treated with BRAF-targeted therapy harbored amplifications of BRAF and cell cycle genes more frequently than therapy-naive patients. Thirty-six patients (6.3%) were treated following the molecular tumor board (MTB) recommendations. CONCLUSION: Actionable gene alterations in BRAF , NRAS , NF1 , and KIT are common in Japanese patients with melanoma. However, few patients were treated according to the MTB recommendations, suggesting that there is an unmet need to increase accessibility to gene-matched clinical trials in Japan.


  • Top Cited Papers
    Open Access

    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies

    by Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung-Jue Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, Masahiro Sugihara, et al.

    HER2-expressing salivary gland carcinoma (SGC) is associated with poor prognosis. Trastuzumab deruxtecan (T-DXd, DS-8201) has shown evidence of antitumor activity for several HER2-expressing solid tumors in multiple studies. This study aimed to present the efficacy and safety of T-DXd in patients with HER2-expressing SGC from a pooled analysis. Patients with HER2-expressing SGC were pooled from two phase I, open-label studies of T-DXd: a two-phase, multiple-dose, first-in-human study (NCT02564900) and a single-sequence crossover drug–drug interaction study (NCT03383692). Endpoints included efficacy (objective response rate [ORR], duration of response [DoR] and progression-free survival [PFS]) and safety. This pooled analysis included 17 patients with SGC (median age: 57 years; male: 88.2%); median (range) follow-up duration was 12.0 (2.3–‍34.8) months. Among these patients, 14 had received prior HER2-targeted agents and 13 had undergone prior radiotherapy. The investigator-assessed confirmed ORR was 58.8% (95% confidence interval [CI], 32.9–‍81.6). The median (95% CI) DoR and PFS were 17.6 months (4.0 to not evaluable [NE]) and 20.5 months (11.1–NE), respectively. All 17 patients reported treatment-emergent adverse events (TEAEs); 76.5% reported TEAEs of grade ≥3. The most common TEAEs were decreased appetite (94.1%), nausea (88.2%) and neutrophil count decreased (76.5%). Of the 17 patients, five (29.4%) reported adjudicated drug-related interstitial lung disease (grade 1, n = 3; grade 2, n =1; grade 3, n = 1). The results of this pooled analysis provide evidence that clinical benefit is achievable with T-DXd in patients with HER2-expressing SGC. FIH study, NCT02564900; DDI study, NCT03383692


  • Open Access

    Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers

    by Kanako Hagio, Junko Kikuchi, Kohichi Takada, Hiroki Tanabe, Minako Sugiyama, Yoshihito Ohhara, Toraji Amano, Satoshi Yuki, Yoshito Komatsu, Takahiro Osawa, et al.

    Comprehensive genomic profiling (CGP) tests have been covered by public insurance in Japan for patients with advanced solid tumors who have completed or are completing standard treatments or do not have them. Therefore, genotype‐matched drug candidates are often unapproved or off‐label, and improving clinical trial access is critical, involving the appropriate timing of CGP tests. To address this issue, we analyzed the previous treatment data for 441 patients from an observational study on CGP tests discussed by the expert panel at Hokkaido University Hospital between August 2019 and May 2021. The median number of previous treatment lines was two; three or more lines accounted for 49%. Information on genotype‐matched therapies was provided to 277 (63%). Genotype‐matched clinical trials were ineligible because of an excess number of previous treatment lines or use of specific agents were found in 66 (15%) patients, with the highest proportion in breast and prostate cancers. Many patients met the exclusion criteria of one to two or more treatment lines across cancer types. In addition, previous use of specific agents was a frequent exclusion criterion for breast, prostate, colorectal, and ovarian cancers. The patients with tumor types with a low median number (two or fewer) of previous treatment lines, including most rare cancers, primary unknown cancers, and pancreatic cancers, had significantly fewer ineligible clinical trials. The earlier timing of CGP tests may improve access to genotype‐matched clinical trials, with their proportion varying by cancer type. Each relevant society needs to advocate the desirable timing of CGP testing nationwide.


  • Open Access

    Crystalline silica-exposed human lung epithelial cells presented enhanced anchorage-independent growth with upregulated expression of BRD4 and EZH2 in autocrine and paracrine manners

    by Motoo Katabami, Ichiro Kinoshita, Shin Ariga, Yasushi Shimizu, Hirotoshi Dosaka-Akita

    Crystalline silica-induced inflammation possibly facilitates carcinogenesis. Here, we investigated its effect on lung epithelium damage. We prepared conditioned media of immortalized human bronchial epithelial cell lines (hereinafter bronchial cell lines) NL20, BEAS-2B, and 16HBE14o- pre-exposed to crystalline silica (autocrine crystalline silica conditioned medium), a phorbol myristate acetate-differentiated THP-1 macrophage line, and VA13 fibroblast line pre-exposed to crystalline silica (paracrine crystalline silica conditioned medium). As cigarette smoking imposes a combined effect on crystalline silica-induced carcinogenesis, a conditioned medium was also prepared using the tobacco carcinogen benzo[a]pyrene diol epoxide. Crystalline silica-exposed and growth-suppressed bronchial cell lines exhibited enhanced anchorage-independent growth in autocrine crystalline silica and benzo[a]pyrene diol epoxide conditioned medium compared with that in unexposed control conditioned medium. Crystalline silica-exposed nonadherent bronchial cell lines in autocrine crystalline silica and benzo[a]pyrene diol epoxide conditioned medium showed increased expression of cyclin A2, cdc2, and c-Myc, and of epigenetic regulators and enhancers, BRD4 and EZH2. Paracrine crystalline silica and benzo[a]pyrene diol epoxide conditioned medium also accelerated the growth of crystalline silica-exposed nonadherent bronchial cell lines. Culture supernatants of nonadherent NL20 and BEAS-2B in crystalline silica and benzo[a]pyrene diol epoxide conditioned medium had higher EGF concentrations, whereas those of nonadherent 16HBE14o- had higher TNF-α levels. Recombinant human EGF and TNF-α promoted anchorage-independent growth in all lines. Treatment with EGF and TNF-α neutralizing antibodies inhibited cell growth in crystalline silica conditioned medium. Recombinant human TNF-α induced BRD4 and EZH2 expression in nonadherent 16HBE14o-. The expression of γH2AX occasionally increased despite PARP1 upregulation in crystalline silica-exposed nonadherent lines with crystalline silica and benzo[a]pyrene diol epoxide conditioned medium. Collectively, crystalline silica- and benzo[a]pyrene diol epoxide-induced inflammatory microenvironments comprising upregulated EGF or TNF-α expression may promote crystalline silica-damaged nonadherent bronchial cell proliferation and oncogenic protein expression despite occasional γH2AX upregulation. Thus, carcinogenesis may be cooperatively aggravated by crystalline silica-induced inflammation and genotoxicity.


  • Open Access

    Expression of Karyopherin Alpha 2 and Karyopherin Beta 1 Correlate with Poor Prognosis in Gastric Cancer

    by Yoshihito Ohhara, Ichiro Kinoshita, Akira Suzuki, Makoto Imagawa, Jun Taguchi, Takuro Noguchi, Satoshi Takeuchi, Yasushi Shimizu, Hideyuki Seki, Junichi Suzuki, et al.

    Introduction: Karyopherin alpha 2 (KPNA2) and karyopherin beta 1 (KPNB1) constitute nuclear transport protein complexes involved in nuclear import and are significant in tumor progression. Although high KPNA2 expression was associated with poor prognosis in solid tumors, the relationship between KPNA2 and KPNB1 expression and their prognostic role in gastric cancer (GC) remains unclear. Methods: Immunohistochemistry was used to correlate the expression of KPNA2 and KPNB1 with various features, including clinicopathological characteristics in 130 patients with GC and survival in 94 patients with invasive lesions extending to the submucosa or deeper. Results: High expression of KPNA2 and KPNB1 was found in 25% and 36% of the patients, respectively. Both were significantly related to tumor depth, lymph node metastasis, lymphatic invasion, venous invasion, and Ki-67 expression. KPNA2 expression was significantly related to that of KPNB1 (p < 0.001). Patients with high KPNB1 expression had poorer prognosis than those with low expression (p = 0.027), as was also observed in case of KPNA2 (p < 0.001). Patients with high expression of both KPNA2 and KPNB1 accounted for 18% and had a poorer prognosis than those with high expression of either and those with low expression of both (p = 0.001). Multivariate analysis revealed that high expression of both KPNA2 and KPNB1 was an independent prognostic factor in patients with GC (hazard ratio, 3.46; 95% confidence interval, 1.64–2.73, p = 0.001). Conclusion: KPNA2 expression was correlated with KPNB1 expression, and high co-expression of KPNA2 and KPNB1 may represent a strong prognostic biomarker in GC.


  • O12-4 Clinical significance of comprehensive genomic profiling in pediatric cancer patients

    by Minako Sugiyama, Junko Kikuchi, Yoshihito Ohhara, Kanako Hagio, Toraji Amano, Emi Takakuwa, C. Kanako Hatanaka, Yutaka Hatanaka, Atsushi Manabe, Takeo Sarashina, et al.

  • Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan

    by Junko Kikuchi, Yoshihito Ohhara, Kohichi Takada, Hiroki Tanabe, Kazuteru Hatanaka, Toraji Amano, Kanako C Hatanaka, Yutaka Hatanaka, Takashi Mitamura, Momoko Kato, et al.

    Comprehensive cancer genomic profiling has been used recently for patients with advanced solid cancers. Two cancer genomic profiling tests for patients with no standard treatment are covered by Japanese public health insurance since June 2019. We prospectively analyzed data of 189 patients with solid cancers who underwent either of the two-cancer genomic profiling tests at Hokkaido University Hospital and its liaison hospitals and whose results were discussed in molecular tumor board at Hokkaido University Hospital between August 2019 and July 2020. All 189 patients had appropriate results. Actionable gene alterations were identified in 93 patients (49%). Frequent mutations included PIK3CA (12%) mutation, BRCA1/2 alteration (7%), ERBB2 amplification (6%) and tumor mutation burden-High (4%). The median turnaround time from sample shipping to acquisition by the expert panel was 26 days. Although 115 patients (61%) were provided with information for genotype-matched therapies, only 21 (11%) received them. Notably, four of eight patients below the age of 20 years were provided information for genotype-matched therapies, and three received them. Their response rates and disease control rates were 29% and 67%, respectively. Most patients who did not undergo the genotype-matched therapies were provided information for only investigational drugs in phases I and II at distant clinical trial sites in central Japan. Twenty-six patients were informed of suspected germline findings, while 11 patients (42%) received genetic counseling. The publicly reimbursed cancer genomic profilings may lead to the modest but favorable therapeutic efficacy of genotype-matched therapy for solid cancer patients with no standard therapy. However, poor access to genotype-matched therapy needs to be resolved.